American Academy of Dermatology

The combination showed efficacy in a predominantly female, treatment-experienced, high-BMI population.

Merola discussed how new data from AAD 2026 suggest broader anti-inflammatory properties of GIP/GLP-1 RAs may offer benefits beyond weight loss.

The findings extend the radiographic dataset for risankizumab in PsA to 244 weeks — the longest such follow-up reported from the KEEPsAKE program.

Data from the POETYK PsA-2 trial examining deucravacitinib were presented at the 2025 American Academy of Dermatology annual meeting.

A post-hoc analysis shows that the human monoclonal antibody was linked to sustained improvements according to different disease measurements through week 52.